Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Cognition Disorders × Lomustine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Central Nervous System Neoplasms 11 Glioblastoma 10 Brain Neoplasms 8 Astrocytoma 7 Glioma 5 Oligodendroglioma 4 Gliosarcoma 3 Medulloblastoma 2 Leukemia, Myeloid, Acute 2 Spinal Cord Neoplasms 1 Optic Nerve Glioma 1 Neoplasms, Plasma Cell 1 Neoplasms 1 Neoplasm Recurrence, Local 1 Multiple Myeloma 1 Cognition Disorders 1

Interventions

Mental Status and Dementia Tests 1 Lomustine 1 DNA Methylation 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01290939 2021-02-15

Bevacizumab and Lomustine for Recurrent GBM

European Organisation for Research and Treatment of Cancer - EORTC

Phase 3 Completed

Brain Neoplasms, Cognition Disorders, Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡